Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The new radio system is aimed to enable qTerm as a private, secured, MESH radio communication network. GBT/Tokenize has developed the technology for a radio based network that can be used for IoT and mobile devices. A successful MESH network system was tested in 2019.$GTCH
GBT Tokenize (“GBT/Tokenize”) commenced a new radio system development for its qTerm device.$GTCH
GBT/Tokenize's Machine Learning system is aimed to analyze the biofield data and possible detection of onset disease. Based on Kirlian images and patterns, GBT/Tokenize's AI seeks to observe, study, analyze and ultimately alert physicians about possible underlying illnesses or symptoms.$GTCH
GBT/Tokenize encourages public participation in its research. Scientists and researchers that are interested to participate in our research are welcome to send us their material for evaluation at kirlian_research@qterm.me$GTCH
GBT Tokenize Commencing Open Public Research in Kirlian Electrophotography Technique. $GTCH
GBT Technologies Inc. 's (OTC Pink: GTCH) AI-powered qTerm human vital signs device is adding a blood pressure measurement feature, according to a recent press release.$GTCH
GBT plans to continue expanding the features and AI capabilities of the device on subsequent versions as well. In fact, it was recently announced that the company's joint venture, GBT Tokenize, had begun developing a new radio system for the device.$GTCH
Immune Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.$IMUN
GBT Technologies Inc. 's (OTC Pink: GTCH) AI-powered qTerm human vital signs device is adding a blood pressure measurement feature.$GTCH
GBT is a California-based company that is introducing what can only be seen as a disruptive technology in an industry that is red hot and seemingly growing exponentially year-over-year.$GTCH
GBT Technologies (GBT)is ideally positioned to compete in what Gartner, a leading research and advisory firm, estimates will be an almost $4-trillion market by 2022.$GTCH
Today’s positive coverage of Immune Therapeutics by such a well-respected and internationally distributed publication, such as Forbes, is a yet another indication that Immune has truly embarked on a new era of growth and expansion as we look towards the bright future that lays ahead.$IMUN
Immune Therapeutics Inc.'s platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Both therapies have been decades in the making at institutions such as the Pennsylvania State University Medical School at Hershey, University of Chicago, State University of New York, and Multiple Sclerosis Center at UCSF.$IMUN
For Immune Therapeutics, Inc. (Ticker: IMUN) and it’s shareholders who hold a considerable stake in Cytocom this means that the value for all of the years of support and collaboration with Cytocom can be realized.$IMUN
GBT Technologies Inc. $GTCHhas chosen the medical field as the technology’s entry point to show off just how disruptive a technology it can be.$GTCH
Immune Therapeutics is currently designing studies using Lodonal™ and IRT-101 as a monotherapy or in conjunction with other potential treatments.$IMUN
Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced it has initiated a corporate plan to drive shareholder value.Recent economic events require that Immune revisit its business model and explore new opportunities to drive shareholder value.$IMUN
GBT Technologies Inc. has a vast portfolio of intellectual property that spans both the Artificial Intelligence (AI) and Internet of Things (IoT) markets. But the company’s central focus is on a technology called “Avant! AI”—a technology that could become commonplace in both businesses and households worldwide. It is the extremely promising potential of Avant! that has GBT Technologies (GBT) ideally positioned to compete in what Gartner, a leading research and advisory firm, estimates will be an almost $4-trillion market by 2022.$GTCH
GBT Technologies Inc.'s goal for GopherInsight Microchips is to be installed in billions of mobile devices in the next few years. This will allow GTCH to create private secure communications networks that will enormously benefit organizational and individual users.$GTCH
GBT Technologies Platform Technology is called GopherInsight™, which uses “public” RF spectrum to facilitate a private network between enabled devices.$GTCH
GBT Technologies Inc. (OTCPINK:GTCH) has announced that its joint venture, GBT Tokenize Corp., has concluded the qTerm device's features, with the addition of two features. The AI-powered qTerm device, which "can be easily attached to the back of a smartphone or used as a standalone apparatus," measures the user's body temperature, blood oxygen level and heart rate, and alerts the user if any measurements are deemed a concern.$GTCH
GBT decided to enhance its Epsilon reliability software package, preparing for advanced nodes like 5nm and the upcoming 3nm. This is a major decision since 7nm and 5nm are still a traditional FinFet approach, but with the upcoming 3nm is another device architecture.$GTCH
GBT/Tokenize's AI seeks to observe, study, analyze and ultimately alert physicians about possible underlying illnesses or symptoms. If developed and commercialized, such a system can be efficient for remote telemedicine diagnostics and medical advice.$GTCH
GBT Technologies Inc.(OTC Pink: GTCH) AI-powered qTerm human vital signs device is adding a blood pressure measurement feature, according to a recent press release.$GTCH
For Immune Therapeutics, Inc. (Ticker: IMUN) and it’s shareholders who hold a considerable stake in Cytocom this means the value for all of the years of support and collaboration with Cytocom can be realized. The Cytocom platform technologies and product pipeline, in combination with Cleveland BioLabs, have the potential to drive significant future growth in Immune’s shareholder value.$IMUN
The merger with Cytocom will allow Immune Therapeutics to add the strength of their science and bright perspectives associated with Entolimod development in cancer treatment and radiation defense arenas with a string of immunomodulators developed by Cytocom to form a powerful blend of conceptually and scientifically aligned products.$IMUN
or Immune Therapeutics (OTCPK:IMUN +362.0%) the combination of Cytocom and Cleveland BioLabs business means that shareholders who hold a considerable stake in Cytocom can realize value.$IMUN
Immune Therapeutics, Inc. (OTC Pink: IMUN) ("Immune" "IMUN" or the "Company") is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases.$IMUN
Immune Therapeutics company is involved in acquiring the patent for the development of new uses of opioid-related immune- therapies, such as low dose naltrexone (LDN) and Methionine [Met5]-enkephalin (MENK). It focuses on to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases.$IMUN
Immune Therapeutics Inc is a specialty pharmaceutical company operating in the USA. It engages in the commercialization of patented therapies focused on the activation and re-balancing of the body's immune system. It focuses on to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases.$IMUN
GBT Technologies, Inc. (OTC PINK: GTCH) (GBT) is among a handful of companies that are developing Artificial Intelligence (AI) and Internet of Things (IoT) solutions that are expected to transform the future of the healthcare industry. Both segments of the industry, AI and IoT, are growing exponentially, and GBT’s technology is ideally positioned to succeed in this burgeoning marketplace.$GTCH
GBT Technologies is targeting multiple applications for its Avant! AI, including autonomous machines and robots, as well as sports handicapping and more. So, with AI continuing to be one of the most vital and fertile technology fields in the so-called Fourth Industrial Revolution, one can expect to see more applications and use cases emerge as the technology develops and the already impressive benefits continue to accrue.$GTCH
Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s collaborator Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial.$IMUN
?
GBT Technologies, Inc. (OTC Pink: GTCH) an emerging technology company focusing on artificial intelligence innovations and chip design was directing research and development resources into healthcare and medicine prior to the pandemic, using the company's Avant! AI licensed technology (https://www.avant-ai.net) and introducing as "derivative" a new tool - https://www.hmd.care as beta version.$GTCH
GBT's invention goes beyond 3D concept with multi-plane silicon structures, for example honeycomb, hexagonal and further multi-planetary structures, in order to significantly increase silicon surface area. These types of structures are designed to enable the design and manufacture chips with multi-trillion transistors on die, creating new horizons for mega-chips with mega features.$GTCH
GBT's 3D microchip patent is protecting GBT's futuristic integrated circuit technology which introduces new systems and methods for microchip's manufacturing. The invention is designed to present a new die structure and orientation with a focus on deep nanometer range.$GTCH
GBT/Tokenize has decided to introduce an initial release of qTerm. The early release of the product will include body temperature, heart rate and blood oxygen level features and is targeted to be released by the end of this year. These three (3) vitals measurements are essential to assist with the pandemic crisis since they provide important health factors for early viral infection detection. The Blood Pressure feature is planned to be released in qTerm second release, planned for Q1 2021.$IMUN
GBT/Tokenize's blood pressure solution will comprise a complete integrated optical sensor module, and an embedded microcontroller. A sensing firmware algorithm will provide the operation and control of the entire system. Such method is called photoplethysmography (PPG) and its goal is to detect blood volume changes in the microvascular tissues.$IMUN
Immune Therapeutics, Inc. (OTCQB:IMUN) (“Immune” “IMUN” or the “Company”), a clinical late stage biopharmaceutical company focused on the development of two immunomodulating therapies (IRT-103 “Lodonal” and IRT-101 “MENK”) for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDs. $IMUN
GBT's 3D microchip patent is protecting GBT's futuristic integrated circuit technology which introduces new systems and methods for microchip's manufacturing. The invention is designed to present a new die structure and orientation with a focus on deep nanometer range. The goal of the technology is to enable manufacturing more devices on silicon in order to achieve more circuits/features on die.$GTCH